Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: A substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

HIV Medicine

Volumn 16, Issue S1, 2015, Pages 129-136

  Matthews, Gv ^a   Neuhaus, J ^b   Bhagani, S ^c   Mehta, Sh ^d   Vlahakis, E ^e   Doroana, M ^f   Naggie, S ^g   Arenas Pinto, A ^h   Peters, L ⁱ   Rockstroh, Jk ^j  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MINNESOTA   (United States)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e Taylor Square Private Clinic ^*  (Australia)

^f HOSPITAL DE SANTA MARIA   (Portugal)

^g DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MRC CLINICAL TRIALS UNIT   (United Kingdom)

ⁱ Rigshospitalet   (Denmark)

^j UNIVERSITY OF BONN   (Germany)

more..

Author keywords

Elastography; FibroScan ; HIV; Liver fibrosis; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS RNA; BIOLOGICAL MARKER;

ADULT; ALGORITHM; ARTICLE; DISEASE COURSE; ELASTOGRAPH; ELASTOGRAPHY; FEMALE; HEPATITIS B; HEPATITIS C; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; TRANSIENT ELASTOGRAPHY; BLOOD; CD4 LYMPHOCYTE COUNT; COMPLICATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; IMMUNOLOGY; LIVER CIRRHOSIS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADULT; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; PREVALENCE;

EID: 84923319551     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12241     Document Type: Article

References (36)

1. Weber R, Sabin CA, Friis-Moller N etal. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Int Med 2006; 166: 1632-1641.
2. Salmon-Ceron D, Lewden C, Morlat P etal. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42: 799-805.
3. Thio CL, Seaberg EC, Skolasky R, Jr etal. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
4. Weber R, Ruppik M, Rickenbach M etal. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14: 195-207.
5. Smith CJ, Ryom L, Weber R etal. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384: 241-248.
6. Wilkins E, Nelson M, Agarwal K etal. British HIV association guidelines for the management of hepatitus viruses in adults infected with HIV 2013. HIV Med 2013; 14 (Suppl 4): 1-71.
7. Quirishi N, Kreuzberg C, Luchters G etal. Effect of antiretroviral therapy on liver-related mortality in patients with HIv and hepatitis C virus coinfection. Lancet 2003; 362: 1708-1713.
8. Brau N, Salvatore M, Rios-Bedoya CF etal. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
9. Anderson JP, Tchetgen Tchetgen EJ, Lo Re V, etal. Antiretroviral therapy reduces the rate of hepatic decompensation among HIV- and hepatitis C virus-coinfected veterans. Clin Infect Dis 2014; 58: 719-727.
10. Mehta AS, Long RE, Comunale MA etal. Increased levels of galactose-deficient anti-Gal immunoglobulin G in the sera of hepatitis C virus-infected individuals with fibrosis and cirrhosis. J Virol 2008; 82: 1259-1270.
11. Vispo E, Moreno A, Maida I etal. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010; 24: 1171-1176.
12. Ingiliz P, Valantin MA, Duvivier C etal. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology 2009; 49: 436-442.
13. Blackard JT, Sherman KE. HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008; 15: 323-330.
14. Balagopal A, Philp FH, Astemborski J etal. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008; 135: 226-233.
15. Brenchley JM, Price DA, Schacker TW etal. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12: 1365-1371.
16. Lo Re V, 3rd, Kallan MJ, Tate JP etal. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med 2014; 160: 369-379.
17. Friedrich-Rust M, Ong MF, Martens S etal. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974.
18. Babiker AG, Emery S, Fatkenheuer G etal. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013; 10 (Suppl 1): S5-S36.
19. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847.
20. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007; 47: 598-607.
21. Sterling RK, Lissen E, Clumeck N etal. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
22. Wai CT, Greenson JK, Fontana RJ etal. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
23. Tahiri M, Sodqi M, Lahdami FE etal. Risk factors for liver fibrosis among human immunodeficiency virus monoinfected patients using the FIB4 index in Morocco. World J Hepatol 2013; 5: 584-588.
24. DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re V, 3rd. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010; 10: 116.
25. Price JC, Seaberg EC, Badri S, Witt MD, D'Acunto K, Thio CL. HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis. J Infect Dis 2012; 205: 1005-1013.
26. Roulot D, Costes JL, Buyck JF etal. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011; 60: 977-984.
27. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003; 37: 1043-1055.
28. Redd AD, Wendel SK, Grabowski MK etal. Liver stiffness is associated with monocyte activation in HIV-infected Ugandans without viral hepatitis. AIDS Res Hum Retroviruses 2013; 29: 1026-1030.
29. Towner WJ, Xu L, Leyden WA etal. The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction. J Acquir Immune Defic Syndr 2012; 60: 321-327.
30. Mendeni M, Foca E, Gotti D etal. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. Clin Infect Dis 2011; 52: 1164-1173.
31. Imbert-Bismut FRV, Peironi L, for the MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075.
32. Castera L, Vergniol J, Foucher J etal. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
33. Sanchez-Conde M, Montes-Ramirez ML, Miralles P etal. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010; 17: 280-286.
34. Poynard T, Ngo Y, Perazzo H etal. Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol 2011; 7: 445-454.
35. Gibellini D, Clo A, Morini S, Miserocchi A, Ponti C, Re MC. Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages. World J Virol 2013; 2: 91-101.
36. INSIGHT START Study Group. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med 2015; 16 (Suppl 1): 1-9.